Developer docs
API playgroundTry for free, no card

Search company profiles

PhoreMost

Full company profile

uuid0002y1s

Namestring
PhoreMost
Legal namestring
PhoreMost Limited
Websiteurl
phoremost.com
Company typeenum
Private
Founded yearint
2015
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery platform, phenotypic screening technology, targeted protein degradation, cancer drug development, molecular glue degraders
Industry3 codes
PRIMARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Drug Discovery Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Collaboration Agreements
TypeLicensing Royalties
Description

PhoreMost generates revenue through multi-project collaboration agreements with pharmaceutical companies. These partnerships typically involve upfront payments, research funding, milestone payments tied to discovery and development achievements, and potential downstream royalties on successful programs. The company operates as a drug discovery engine, developing validated targets that are out-licensed to pharma partners for further development and commercialization.

phoremost.com
2Spin-out Company Equity
TypeLicensing Royalties
Description

PhoreMost has created spin-out companies from its discovery programs (such as NeoPhore), retaining equity stakes in these ventures. This provides potential upside through equity value appreciation and future liquidity events as spinouts advance through development or attract additional investment.

phoremost.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1SITESEEKER
Description

Next-generation phenotypic screening platform that exploits the dynamics of a live-cell environment to uncover hidden druggable target sites across the entire human genome using proprietary PROTEINi technology

phoremost.com
+4 more records
Core offering1 text field

PhoreMost is a Cambridge UK-based biotechnology company that develops proprietary drug discovery platforms (SITESEEKER and GlueSEEKER) built on its PROTEINi protein interference technology to systematically identify cryptic druggable sites on historically "undruggable" protein targets. The company licenses these platforms to pharmaceutical and biotechnology partners through multi-project collaboration agreements and advances its own internal pipeline of small-molecule and bifunctional degrader oncology programs (PMC-001, PMC-002, PMC-003).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 19+ active pharmaceutical partnerships including Boehringer Ingelheim, Roche, and Arvinas, validating the platform's broad applicability.
Product overview1 text field

PhoreMost is a Cambridge UK-based biotechnology company that has developed a unified platform-plus-pipeline business model centred on its SITESEEKER phenotypic screening technology. SITESEEKER, built on the proprietary PROTEINi (protein interference) technology, probes the entire proteome in live cell environments to systematically unmask cryptic druggable sites. The company leverages this platform both for internal drug discovery programmes (PMC-001, PMC-002, PMC-003) and for partnered collaborations with pharmaceutical companies. The GlueSEEKER platform extends capabilities into molecular glue degrader discovery. PhoreMost's model combines platform-as-a-service partnerships with milestone payments and royalties from internal assets progressing toward clinical development.

Product and service6 records
1SITESEEKER Platform
CategoryDrug Discovery Platform
2GlueSEEKER Platform
CategoryDrug Discovery Platform
3PROTEINi Technology
CategoryProprietary Technology Platform
4PMC-001
CategoryInternal Pipeline Asset
5PMC-002
CategoryInternal Pipeline Asset
6PMC-003
CategoryInternal Pipeline Asset
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership17 partners
1Boehringer Ingelheim
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Multi-project drug discovery collaboration using PhoreMost's SITESEEKER platform to identify novel drug targets for Boehringer Ingelheim's pipeline. This flagship partnership demonstrates the platform's applicability to major pharmaceutical R&D operations and provides PhoreMost with significant upfront and milestone payments.

phoremost.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Multi-project drug target discovery collaboration leveraging PhoreMost's platform capabilities to identify novel therapeutic targets for Roche's pharmaceutical pipeline across multiple disease areas.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Multi-project collaboration utilizing PhoreMost's drug discovery technology platforms to identify novel drug targets for Otsuka's pharmaceutical development programs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Multi-target collaboration for targeted protein degradation using PhoreMost's GlueSEEKER molecular glue degradation platform. This partnership combines PhoreMost's target identification capabilities with Arvinas's expertise in PROTAC development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Gene therapy discovery collaboration applying PhoreMost's platform technology to identify novel targets and mechanisms for Oxford Biomedica's gene therapy programs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Drug discovery collaboration focused on identifying novel therapeutic targets using Vernalis's fragment-based drug discovery expertise combined with PhoreMost's SITESEEKER platform.

7Plexxikon
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Collaboration to identify novel drug targets using PhoreMost's platform capabilities, leveraging Plexxikon's expertise in structural biology and fragment-based drug discovery.

phoremost.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-01-01
Description

Structural biology alliance for drug target characterization and validation, combining inStem's structural biology infrastructure with PhoreMost's target identification capabilities.

9C4X Discovery
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Neurodegeneration collaboration focused on identifying novel drug targets for neurodegenerative diseases using PhoreMost's platform technology.

phoremost.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Multi-target collaboration with POLARISqb, combining computational drug design capabilities with PhoreMost's target identification platform.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Collaboration for glioma therapeutic development, applying PhoreMost's SITESEEKER platform to identify novel targets for this aggressive brain cancer indication.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

NeoPhore is a spin-out company created by PhoreMost to advance novel immuno-oncology therapeutics discovered through the SITESEEKER platform, representing the company's approach to creating value through company formation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Collaboration on neurodegenerative disease research, combining PhoreMost's platform with academic expertise from the University of Cambridge's world-leading neuroscience research programs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Innovate UK funding collaboration for research programs conducted at the Babraham Research Campus, where PhoreMost has conducted collaborative research in partnership with the institute.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Drug discovery collaboration with o2h discovery, combining their medicinal chemistry capabilities with PhoreMost's target identification platform for integrated drug discovery programs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Alliance for novel targets in cancer, aging and immune system, combining The Wistar Institute's renowned cancer research expertise with PhoreMost's platform capabilities for target discovery.

17NeoCura
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Research collaboration with NeoCura, an emerging biotech company focused on novel cancer therapeutics, applying PhoreMost's platform to identify new targets and mechanisms.

phoremost.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Repare uses proprietary genomics and phenotypic screening to identify novel precision oncology targets, a screening-by-platform business model that closely parallels PhoreMost's SITESEEKER approach to discovering previously inaccessible cancer targets.

TypeDirect peer
Description

Foghorn leverages a chromatin biology platform to find druggable sites on chromatin regulatory complexes historically considered undruggable, mirroring PhoreMost's core thesis of unmasking cryptic targets via proprietary screening chemistry.

TypeDirect peer
Description

Neomorph was a clinical-stage molecular glue degrader biotech with a proprietary ligase discovery platform before its $1.7B acquisition by AbbVie in 2025 — a near-direct comp for PhoreMost's GlueSEEKER, demonstrating the M&A premium for differentiated TPD platforms.

TypeBroad incumbent
Description

Schrödinger is a larger computational drug discovery platform company partnering with pharma across therapeutic areas; though it focuses on physics-based computation rather than wet-lab phenotypic screening, it serves the same platform-collaboration business archetype as PhoreMost's SITESEEKER offering.

TypeBroad incumbent
Description

Exscientia is a UK-based AI-driven drug discovery company with multiple Big Pharma collaborations; it is a broader, more mature version of PhoreMost's platform-plus-partnership model and shares Cambridge UK presence.

6C4X Discovery
TypeRegional player
Description

C4X Discovery is a Manchester UK-based structure-based and phenotypic drug discovery company partnered with PhoreMost on neurodegeneration targets; similar UK SME scale and overlapping target-discovery approach make it a UK peer in the same niche.

TypeOthers
Description

NeoPhore was spun out of PhoreMost in 2017 with Sixth Element Capital backing to develop small-molecule immuno-oncology therapies built on PhoreMost's SITESEEKER platform; it is economically linked to PhoreMost and serves as a use-case reference for the platform's value-creation pathway.

TypeDirect peer
Description

Kymera is a clinical-stage TPD company building a pipeline of heterobifunctional and molecular glue degraders using novel ligases — directly analogous to PhoreMost's GlueSEEKER platform strategy and PMC-003's FBXO22-driven degrader concept.

TypeDirect peer
Description

Arvinas is a clinical-stage targeted protein degradation company pioneering PROTAC and molecular glue degraders, directly overlapping PhoreMost's GlueSEEKER and FBXO22-based degrader work; it is both an active collaboration partner (multi-target 2022 deal) and a direct competitor in TPD modality discovery.

TypeDirect peer
Description

Monte Rosa is a Boston-based biotech developing molecular glue degraders leveraging proprietary E3 ligase biology, comparably focused on uncovering undruggable protein targets through novel ligase chemistry. Highly comparable to PhoreMost's GlueSEEKER platform and degrader pipeline stance.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PhoreMost

Drug Discovery Servicesphoremost.com

PhoreMost firmographics

Firmographics
Name
PhoreMost
Legal name
PhoreMost Limited
Website
https://phoremost.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

PhoreMost industry classification

Industry
Product category
Drug Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Keywords

  • Drug discovery platform
  • Phenotypic screening technology
  • Targeted protein degradation
  • Cancer drug development
  • Molecular glue degraders

Where PhoreMost is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

PhoreMost business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Collaboration Agreements: PhoreMost generates revenue through multi-project collaboration agreements with pharmaceutical companies. These partnerships typically involve upfront payments, research funding, milestone payments tied to discovery and development achievements, and potential downstream royalties on successful programs. The company operates as a drug discovery engine, developing validated targets that are out-licensed to pharma partners for further development and commercialization.
  2. Spin-out Company Equity: PhoreMost has created spin-out companies from its discovery programs (such as NeoPhore), retaining equity stakes in these ventures. This provides potential upside through equity value appreciation and future liquidity events as spinouts advance through development or attract additional investment.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

PhoreMost product offering

Product offering

Core offering

PhoreMost is a Cambridge UK-based biotechnology company that develops proprietary drug discovery platforms (SITESEEKER and GlueSEEKER) built on its PROTEINi protein interference technology to systematically identify cryptic druggable sites on historically "undruggable" protein targets. The company licenses these platforms to pharmaceutical and biotechnology partners through multi-project collaboration agreements and advances its own internal pipeline of small-molecule and bifunctional degrader oncology programs (PMC-001, PMC-002, PMC-003).

Product overview

PhoreMost is a Cambridge UK-based biotechnology company that has developed a unified platform-plus-pipeline business model centred on its SITESEEKER phenotypic screening technology. SITESEEKER, built on the proprietary PROTEINi (protein interference) technology, probes the entire proteome in live cell environments to systematically unmask cryptic druggable sites. The company leverages this platform both for internal drug discovery programmes (PMC-001, PMC-002, PMC-003) and for partnered collaborations with pharmaceutical companies. The GlueSEEKER platform extends capabilities into molecular glue degrader discovery. PhoreMost's model combines platform-as-a-service partnerships with milestone payments and royalties from internal assets progressing toward clinical development.

Differentiator

Problem solved

Functional benefit

Brands

  • SITESEEKER: Next-generation phenotypic screening platform that exploits the dynamics of a live-cell environment to uncover hidden druggable target sites across the entire human genome using proprietary PROTEINi technology
  • GlueSEEKER
  • PMC-001
  • PMC-002
  • PMC-003

Products and services

  • SITESEEKER Platform
  • GlueSEEKER Platform
  • PROTEINi Technology
  • PMC-001
  • PMC-002
  • PMC-003

Quantifiable outcome

  • 19+ active pharmaceutical partnerships including Boehringer Ingelheim, Roche, and Arvinas, validating the platform's broad applicability.

Companies that use PhoreMost

Customer profile

Named customers9 records

Segments2 records

Ideal customer profiles2 records

PhoreMost technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

PhoreMost partnerships and signals

Strategic signal

Partnerships

17 partnerships are on record, tiered flagship, core and minor.

  • Boehringer IngelheimflagshipStrategic or Co-development Partner · 1 January 2021Multi-project drug discovery collaboration using PhoreMost's SITESEEKER platform to identify novel drug targets for Boehringer Ingelheim's pipeline. This flagship partnership demonstrates the platform's applicability to major pharmaceutical R&D operations and provides PhoreMost with significant upfront and milestone payments.
  • RocheflagshipStrategic or Co-development Partner · 1 January 2021Multi-project drug target discovery collaboration leveraging PhoreMost's platform capabilities to identify novel therapeutic targets for Roche's pharmaceutical pipeline across multiple disease areas.
  • Otsuka PharmaceuticalcoreStrategic or Co-development Partner · 1 January 2021Multi-project collaboration utilizing PhoreMost's drug discovery technology platforms to identify novel drug targets for Otsuka's pharmaceutical development programs.
  • ArvinascoreStrategic or Co-development Partner · 1 January 2021Multi-target collaboration for targeted protein degradation using PhoreMost's GlueSEEKER molecular glue degradation platform. This partnership combines PhoreMost's target identification capabilities with Arvinas's expertise in PROTAC development.
  • Oxford BiomedicacoreStrategic or Co-development Partner · 1 January 2021Gene therapy discovery collaboration applying PhoreMost's platform technology to identify novel targets and mechanisms for Oxford Biomedica's gene therapy programs.
  • Vernalis (Ligand)coreStrategic or Co-development Partner · 1 January 2021Drug discovery collaboration focused on identifying novel therapeutic targets using Vernalis's fragment-based drug discovery expertise combined with PhoreMost's SITESEEKER platform.
  • PlexxikoncoreStrategic or Co-development Partner · 1 January 2021Collaboration to identify novel drug targets using PhoreMost's platform capabilities, leveraging Plexxikon's expertise in structural biology and fragment-based drug discovery.
  • inStem (CCBT)coreTechnology or Integration · 1 January 2021Structural biology alliance for drug target characterization and validation, combining inStem's structural biology infrastructure with PhoreMost's target identification capabilities.
  • C4X DiscoveryminorStrategic or Co-development Partner · 1 January 2021Neurodegeneration collaboration focused on identifying novel drug targets for neurodegenerative diseases using PhoreMost's platform technology.
  • POLARISqbminorStrategic or Co-development Partner · 1 January 2021Multi-target collaboration with POLARISqb, combining computational drug design capabilities with PhoreMost's target identification platform.
  • Sentinel OncologycoreStrategic or Co-development Partner · 1 January 2021Collaboration for glioma therapeutic development, applying PhoreMost's SITESEEKER platform to identify novel targets for this aggressive brain cancer indication.
  • NeoPhorecoreStrategic or Co-development Partner · 1 January 2021NeoPhore is a spin-out company created by PhoreMost to advance novel immuno-oncology therapeutics discovered through the SITESEEKER platform, representing the company's approach to creating value through company formation.
  • University of CambridgecoreStrategic or Co-development Partner · 1 January 2021Collaboration on neurodegenerative disease research, combining PhoreMost's platform with academic expertise from the University of Cambridge's world-leading neuroscience research programs.
  • Babraham InstitutecoreStrategic or Co-development Partner · 1 January 2021Innovate UK funding collaboration for research programs conducted at the Babraham Research Campus, where PhoreMost has conducted collaborative research in partnership with the institute.
  • o2h discoveryminorStrategic or Co-development Partner · 1 January 2021Drug discovery collaboration with o2h discovery, combining their medicinal chemistry capabilities with PhoreMost's target identification platform for integrated drug discovery programs.
  • The Wistar InstitutecoreStrategic or Co-development Partner · 1 January 2021Alliance for novel targets in cancer, aging and immune system, combining The Wistar Institute's renowned cancer research expertise with PhoreMost's platform capabilities for target discovery.
  • NeoCuraminorStrategic or Co-development Partner · 1 January 2021Research collaboration with NeoCura, an emerging biotech company focused on novel cancer therapeutics, applying PhoreMost's platform to identify new targets and mechanisms.

Scale indicators3 records

Recent moves8 records

Expansion highlights6 records

PhoreMost competitors and assessment

Company assessment

Direct peers

  • Repare Therapeutics: Repare uses proprietary genomics and phenotypic screening to identify novel precision oncology targets, a screening-by-platform business model that closely parallels PhoreMost's SITESEEKER approach to discovering previously inaccessible cancer targets.
  • Foghorn Therapeutics: Foghorn leverages a chromatin biology platform to find druggable sites on chromatin regulatory complexes historically considered undruggable, mirroring PhoreMost's core thesis of unmasking cryptic targets via proprietary screening chemistry.
  • Neomorph: Neomorph was a clinical-stage molecular glue degrader biotech with a proprietary ligase discovery platform before its $1.7B acquisition by AbbVie in 2025 — a near-direct comp for PhoreMost's GlueSEEKER, demonstrating the M&A premium for differentiated TPD platforms.
  • Kymera Therapeutics: Kymera is a clinical-stage TPD company building a pipeline of heterobifunctional and molecular glue degraders using novel ligases — directly analogous to PhoreMost's GlueSEEKER platform strategy and PMC-003's FBXO22-driven degrader concept.
  • Arvinas: Arvinas is a clinical-stage targeted protein degradation company pioneering PROTAC and molecular glue degraders, directly overlapping PhoreMost's GlueSEEKER and FBXO22-based degrader work; it is both an active collaboration partner (multi-target 2022 deal) and a direct competitor in TPD modality discovery.
  • Monte Rosa Therapeutics: Monte Rosa is a Boston-based biotech developing molecular glue degraders leveraging proprietary E3 ligase biology, comparably focused on uncovering undruggable protein targets through novel ligase chemistry. Highly comparable to PhoreMost's GlueSEEKER platform and degrader pipeline stance.

Broad incumbents

  • Schrödinger: Schrödinger is a larger computational drug discovery platform company partnering with pharma across therapeutic areas; though it focuses on physics-based computation rather than wet-lab phenotypic screening, it serves the same platform-collaboration business archetype as PhoreMost's SITESEEKER offering.
  • Exscientia: Exscientia is a UK-based AI-driven drug discovery company with multiple Big Pharma collaborations; it is a broader, more mature version of PhoreMost's platform-plus-partnership model and shares Cambridge UK presence.

Regional players

  • C4X Discovery: C4X Discovery is a Manchester UK-based structure-based and phenotypic drug discovery company partnered with PhoreMost on neurodegeneration targets; similar UK SME scale and overlapping target-discovery approach make it a UK peer in the same niche.

Others

  • NeoPhore: NeoPhore was spun out of PhoreMost in 2017 with Sixth Element Capital backing to develop small-molecule immuno-oncology therapies built on PhoreMost's SITESEEKER platform; it is economically linked to PhoreMost and serves as a use-case reference for the platform's value-creation pathway.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights6 records

Customer concentration

PhoreMost social profiles

Digital presence

PhoreMost financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PhoreMost leadership team

Management profile

Number of profiles

Profiles13 records

PhoreMost subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

PhoreMost funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PhoreMost M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PhoreMost

What does PhoreMost do?

PhoreMost is a Cambridge UK-based biotechnology company that develops proprietary drug discovery platforms (SITESEEKER and GlueSEEKER) built on its PROTEINi protein interference technology to systematically identify cryptic druggable sites on historically "undruggable" protein targets. The company licenses these platforms to pharmaceutical and biotechnology partners through multi-project collaboration agreements and advances its own internal pipeline of small-molecule and bifunctional degrader oncology programs (PMC-001, PMC-002, PMC-003).

Is PhoreMost a public or private company?

PhoreMost is a private company. It is classified as venture growth investor backed and is currently operating.

When was PhoreMost founded?

PhoreMost was founded in 2015. It employs 11 to 50 people.

Where is PhoreMost based?

PhoreMost is headquartered in Cambridge, United Kingdom, in the Europe region.

How does PhoreMost make money?

Two revenue lines are on record. Pharmaceutical Collaboration Agreements are the primary driver. The others are spin-out Company Equity.

Who are PhoreMost's main competitors?

Direct peers on record are Repare Therapeutics, Foghorn Therapeutics, Neomorph, Kymera Therapeutics, Arvinas and Monte Rosa Therapeutics. Broad incumbents are Schrödinger and Exscientia. C4X Discovery is listed as a regional player. NeoPhore is listed as an others.

Does PhoreMost have an API?

No public API is recorded for PhoreMost.

What industry is PhoreMost in?

PhoreMost's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
News-MedicalPhoreMost announces lead oncology program and appoints Chief Medical Officer to support clinical entryPhoreMost announced its lead oncology program, PMC-001, a small molecule microtubule targeting agent for primary and secondary brain cancers. The company appointed Gabriel Fox as Consulting Chief Medical Officer to lead clinical development, with CMC completed and regulatory filings imminent. The program originates from a collaboration with Sentinel Oncology.The Pharma LetterPhoreMost updates on oncology program and appoints CMOPhoreMost announced its lead oncology program, PMC-001, a small-molecule microtubule targeting agent for primary and secondary brain cancers. The orally bioavailable MTA is positioned to treat glioblastoma and metastatic brain cancers, with potential for further indication expansion. The milestone marks progress toward first-in-human clinical trials.BioWorldPhoremost unveils PMC-001 as lead programPhoremost Ltd. unveiled its lead program, PMC-001, a next-generation small-molecule microtubule-targeting agent for primary and secondary brain cancers. The agent is described as highly differentiated and orally bioavailable.Business Wire BlogPhoreMost Announces Lead Oncology Programme and Appoints Chief Medical Officer to Support Clinical EntryPhoreMost announced its lead oncology programme, PMC-001, a small molecule microtubule targeting agent for primary and secondary brain cancers, progressing toward Phase 1 trials. The company appointed Gabriel Fox as Chief Medical Officer to lead clinical development. Preclinical data show oral activity and CNS penetration, with CMC completed and regulatory filings imminent.Drug Target ReviewThe science behind the systematic discovery of molecular gluesA new scientific approach is advancing the systematic discovery of molecular glues, which have historically been found by chance rather than design. The GlueSEEKER platform, co-developed by Dr. Jia Lu of PhoreMost, enhances the ability to identify and manipulate protein-protein interactions crucial for drug development. This platform could significantly expand the range of druggable proteins, potentially making thousands of previously ‘undruggable’ targets accessible for treatment.Pulse 2.0PhoreMost: Biopharmaceutical Drug Target Company Raises $50 Million (Series B)PhoreMost raised $12 million in additional Series B funding, bringing total raised to over $50 million. Parkwalk Advisors led the investment, with participation from existing investors. The funds will support progression of its degrader programs toward preclinical development.BusinessCloudPhoreMost extends Series B financing to £38mPhoreMost extended its Series B financing to around £38m, led by Parkwalk Advisors with existing investors. The Cambridge biopharmaceutical firm will use the funds to progress its degrader programmes in oncology and inflammatory diseases toward preclinical development and support its GlueSEEKER platform.News-MedicalPhoreMost and Boehringer Ingelheim enter multi-project drug discovery collaborationPhoreMost and Boehringer Ingelheim entered a multi-project drug discovery collaboration, with PhoreMost receiving an upfront payment and research funding plus downstream success-based milestones. The agreement does not disclose further financial terms.PR NewswirePhoreMost and ThinkCyte Collaborate to Advance AI-based Drug DiscoveryPhoreMost Ltd. and ThinkCyte K.K. announced a strategic research partnership on December 13, 2022, to advance AI-based phenotypic drug discovery by combining their proprietary technologies. The collaboration integrates PhoreMost's SITESEEKER platform, which uses Protein Interference technology to uncover druggable sites across the proteome, with ThinkCyte's Ghost Cytometry AI platform for detecting disease-related cellular phenotypes. The partnership aims to develop an integrated approach to high-content phenotypic screening and create differentiated therapies for diseases with unmet clinical need.PhoremostArtificial Intelligence: a revolution in drug discovery?PhoreMost, a Cambridge biotech, is integrating Artificial Intelligence with its phenotypic screening platform to accelerate drug discovery and identify novel targets for undruggable diseases. The company highlighted DeepMind's AlphaFold2 as a transformative tool in the field and announced a collaboration with AI leader XtalPi to investigate epigenetic regulators of tumour progression.